ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection

Part of paid clinical trials in Sacramento, California.

Sponsor
Acurx Pharmaceuticals Inc.
Study ID
NCT07513285
Phase
PHASE2
Status
Recruiting

Conditions

  • Clostridium Difficile Infection Recurrence

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • Ibezapolstat — DRUG
    Ibezapolstat 450 mg po Q12H x14 days

Study Details

Single-arm trial to evaluate the safety and efficacy of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficile infection (CDI).

Key Dates

First listed
Apr 7, 2026
Start date
Aug 6, 2026
Status verified
Aug 2026
Primary completion
Sep 29, 2027
Completion
Nov 24, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ibezapolstat
    Active investigational antibacterial agent

Primary Outcome Measure

Evaluate the rate of CDI Clinical Cure (CC) [ Time Frame: Day 16 ]

Central Contacts

Locations (15)

FacilityCityStateZIPSite coordinators
UC Davis Medical CenterSacramentoCalifornia95817-
Gastroenterolgy Center of ConneticutHamdenConnecticut06518-
Florida International Medical ResearchCoral GablesFlorida33134-
L&A Morales Healthcare, IncHialeahFlorida33012-
San Marcus Research Clinc, IncMiami LakesFlorida33014-
Belis Delgado, MD PAMiami SpringsFlorida33166-
Infectious Disease Consultants of GeorgiaAthensGeorgia30606-
Snake River Research PLLCIdaho FallsIdaho83404-
Endevour HealthSkokieIllinois60077-
Newton-Wellesley HospitalNewtonMassachusetts02462-
University of Massachusetts Memorial HealthcareWorcesterMassachusetts01655-
Henry Ford HospitalDetroitMichigan48202-
DiGiovanna Institute for Medical Education and ResearchMassapequaNew York11758-
Romano, Pontzer & AssociatedPittsburghPennsylvania15215-
University of UtahSalt Lake CityUtah84115-

Find similar trials in Sacramento, CA

Related Studies